10-Q: Movano Faces Delisting, Going Concern Amid Q1 Losses

Movano Inc. reported a 76% revenue decline and a going concern warning for Q1 2025, alongside ongoing Nasdaq delisting threats and a search for strategic alternatives.

Summary

• Reported a net loss of $5.2 million for Q1 2025, an improvement from $5.7 million in Q1 2024.
• Revenue significantly decreased by 76% to $0.2 million in Q1 2025 from $0.9 million in Q1 2024.
• Cash and cash equivalents declined to $4.4 million as of March 31, 2025, from $7.9 million at December 31, 2024.
• Net cash used in operating activities increased to $4.3 million in Q1 2025 from $4.1 million in Q1 2024.
• The company has an accumulated deficit of $153.3 million as of March 31, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern beyond 2025 without additional financing.
• The Board of Directors initiated a process to explore strategic alternatives to maximize shareholder value on May 15, 2025.
• Secured $1.5 million in bridge financing on August 6, 2025, to support the strategic alternatives process, granting a security interest in all assets, including intellectual property.
• Received FDA 510(k) clearance in November 2024 for the pulse oximetry feature in its EvieMED Ring, positioning it as a medical device.
• The company is developing a System-on-a-Chip (SoC) for non-invasive glucose and cuffless blood pressure monitoring, currently undergoing clinical trials.
• Received multiple Nasdaq notices regarding non-compliance with minimum bid price and timely filing rules, but was granted continued listing conditional on filing overdue reports by September 30, 2025, and regaining bid price compliance by October 30, 2025.
• Filed Q1 and Q2 2025 10-Qs on September 24, 2025, meeting one Nasdaq condition.
• Shareholders will vote on a reverse stock split proposal on September 26, 2025, to address the bid price requirement.
• Disclosure controls and procedures were deemed ineffective as of March 31, 2025, due to material weaknesses in internal controls over financial reporting.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a going concern warning, significant revenue decline, and persistent Nasdaq delisting threats. While there are positive developments in product clearance and strategic exploration, the immediate financial and operational challenges are overwhelming.

Positives

• Net loss decreased by 9% to $5.2 million in Q1 2025 compared to $5.7 million in Q1 2024.
• EvieMED Ring received FDA 510(k) clearance for its pulse oximetry feature in November 2024, enabling its sale as a medical device.
• The company believes EvieMED is one of the first patient wearables with FDA clearance on the entire system (hardware and software).
• Actively exploring strategic alternatives to maximize shareholder value.
• Secured $1.5 million in bridge financing to support the strategic alternatives process.
• Met the Nasdaq deadline for filing Q1 and Q2 2025 10-Qs by September 24, 2025.

Negatives

• Revenue plummeted by 76% to $0.2 million in Q1 2025 from $0.9 million in Q1 2024.
• Cash and cash equivalents decreased significantly to $4.4 million at March 31, 2025, from $7.9 million at December 31, 2024.
• Net cash used in operating activities increased to $4.3 million in Q1 2025 from $4.1 million in Q1 2024, indicating higher cash burn.
• Accumulated deficit reached $153.3 million as of March 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond 2025 without additional funding.
• Ongoing non-compliance issues with Nasdaq listing rules, specifically the minimum bid price requirement, necessitating a potential second reverse stock split.
• Disclosure controls and procedures were ineffective due to material weaknesses in internal controls over financial reporting.
• Issued 196,184 shares of common stock through an ATM program in Q1 2025, resulting in shareholder dilution.
• The bridge loan carries a 12.0% interest rate and includes a premium provision that could double the outstanding principal upon certain triggering events, and is secured by all company assets, including IP.

Risks

• Inability to raise additional capital on favorable terms or at all, which could force delays, reductions, or elimination of product development and commercialization efforts.
• Failure to meet Nasdaq's continued listing requirements, particularly the $1.00 minimum bid price, potentially leading to delisting.
• Limited operating history and inability to achieve profitability.
• Dependence on the successful commercialization of the Evie Ring and EvieMED Ring.
• Reliance on third-party manufacturers for product supply, susceptible to interruptions.
• Impact of competitive or alternative products, technologies, and pricing.
• Inability to attract and retain highly qualified personnel.
• Challenges in managing company growth and realizing benefits from future acquisitions or strategic alliances.
• Adverse effects from macroeconomic and geopolitical conditions, including rising inflation.
• Inadequacy of patent protections and challenges in maintaining, enforcing, and defending intellectual property.
• Potential claims of intellectual property infringement, trade secret misappropriation, product liability, or recalls.
• Need to secure required FCC, FDA, and other regulatory approvals.
• Accuracy of market size estimates for products.
• Inability to implement and maintain effective internal control over financial reporting and disclosure controls.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future as it develops its technology and commercializes products. It anticipates requiring additional financing beyond 2025 to fund operations and is actively exploring strategic alternatives, including equity issuance, borrowings, or strategic alliances. The company aims to bring a Class II FDA-cleared device with non-invasive glucose and cuffless blood pressure monitoring to market. Efforts are underway to regain and maintain Nasdaq listing compliance, including a proposed reverse stock split.

Management Comments

• "The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology."
• "The Companys ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future."
• "The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products."
• "These circumstances raise substantial doubt about the Companys ability to continue as a going concern within one year after the date that the financial statements are issued."
• "There can be no assurance that this process [strategic alternatives] will result in any transaction or other strategic change or as to the timing of any such potential agreement or transaction."

Industry Context

Movano Health operates in the competitive and rapidly evolving wearable health technology sector, aiming to differentiate itself by delivering medical-grade data through consumer devices. The FDA 510(k) clearance for its EvieMED Ring's pulse oximetry feature is a significant step, potentially setting it apart from competitors who may only have clearance for individual algorithms. The pursuit of non-invasive glucose and cuffless blood pressure monitoring addresses major unmet needs in the market, but requires substantial R&D and regulatory hurdles. The company's financial struggles and Nasdaq compliance issues highlight the capital-intensive nature and high risks associated with developing and commercializing innovative medical-grade wearables.

Comparison to Industry Standards

• The filing states that EvieMED is believed to be "one of the first patient wearables with FDA clearance on the entire system, both hardware and software, differing from our competition which sometimes gets FDA clearance on an individual algorithm under Software as a Medical Device guidance." This suggests a competitive advantage in regulatory approval scope.
• No specific comparable companies, projects, or results are detailed in the filing for a direct quantitative comparison.

Corporate Governance

Legal Proceedings

• Management is not currently aware of any matters that may have a material adverse impact on the company's business, financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity raises, potential loss of investment due to going concern, and impaired ability to trade common stock if delisted from Nasdaq.
• Employees received Restricted Stock Units (RSUs) in lieu of salary for periods in 2025, indicating potential cash flow constraints for payroll.
• Creditors are impacted by the $1.5 million bridge loan being secured by all of the company's assets, including intellectual property, increasing risk for unsecured creditors and limiting future borrowing capacity.
• Customers may experience potential impact on product availability, support, and future updates if the company's financial situation deteriorates further.

Next Steps

• Continue the process of exploring strategic alternatives to maximize shareholder value.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by October 30, 2025, potentially through a shareholder-approved reverse stock split.
• Secure additional financing to fund operations beyond 2025.
• Continue research and development for non-invasive glucose and cuffless blood pressure monitoring.
• Address and remediate identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company faces critical financial instability, evidenced by a going concern warning, rapidly depleting cash reserves, and a substantial accumulated deficit. Revenue has sharply declined, and operating cash burn has increased. Persistent Nasdaq delisting threats, requiring a potential second reverse stock split, further undermine investor confidence and market liquidity. The identified material weaknesses in internal controls indicate significant governance issues. While product development and FDA clearance are positive, they are overshadowed by the immediate and severe financial and operational challenges, making the stock a high-risk investment with significant downside potential.

Keywords

Wearable technology, Health devices, FDA clearance, Evie Ring, EvieMED Ring, Non-invasive monitoring, Glucose monitoring, Blood pressure monitoring, Going concern, Nasdaq delisting, Strategic alternatives, Financial reporting, Internal controls, Biotechnology, Medical devices